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Autosomal inborn errors of type I IFN immunity and autoantibodies against these cytokines underlie at least 
10% of critical COVID-19 pneumonia cases. We report very rare, biochemically deleterious X-linked TLR7 variants 
in 16 unrelated male individuals aged 7 to 71 years (mean, 36.7 years) from a cohort of 1202 male patients 
aged 0.5 to 99 years (mean, 52.9 years) with unexplained critical COVID-19 pneumonia. None of the 331 asymp-
tomatically or mildly infected male individuals aged 1.3 to 102 years (mean, 38.7 years) tested carry such TLR7 
variants (P = 3.5 × 10−5). The phenotypes of five hemizygous relatives of index cases infected with SARS-CoV-2 
include asymptomatic or mild infection (n = 2) or moderate (n = 1), severe (n = 1), or critical (n = 1) pneumonia. 
Two patients from a cohort of 262 male patients with severe COVID-19 pneumonia (mean, 51.0 years) are hemizygous 
for a deleterious TLR7 variant. The cumulative allele frequency for deleterious TLR7 variants in the male general 
population is <6.5 × 10−4. We show that blood B cell lines and myeloid cell subsets from the patients do not 
respond to TLR7 stimulation, a phenotype rescued by wild-type TLR7. The patients’ blood plasmacytoid dendritic 
cells (pDCs) produce low levels of type I IFNs in response to SARS-CoV-2. Overall, X-linked recessive TLR7 deficiency 
is a highly penetrant genetic etiology of critical COVID-19 pneumonia, in about 1.8% of male patients below the 
age of 60 years. Human TLR7 and pDCs are essential for protective type I IFN immunity against SARS-CoV-2 in 
the respiratory tract.
INTRODUCTION
Interindividual clinical variability in the course of severe acute re-
spiratory syndrome coronavirus 2 (SARS-CoV-2) infection is vast, 
ranging from silent infection to lethal disease (1). The greatest risk 
factor for life-threatening coronavirus disease 2019 (COVID-19) 
pneumonia is age, with a doubling in risk every 5 years from the age 
of 5 years onward and a sharp rise after the age of 65 years (2, 3). 
Other epidemiological risk factors, including common genetic vari-
ants, have only modest effects, with odds ratios of <2 and typically 
<1.5 (2). One intriguing observation is the about 1.5 times higher 
risk in men, which seems to be age independent (2–4). The COVID 
Human Genetic Effort consortium (www.covidhge.com) has enrolled 
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an international cohort of patients, with the aim of investigating 
genetic and immunological causes of life-threatening COVID-19 
pneumonia. We previously tested the hypothesis that critical influ-
enza and critical COVID-19 can be allelic (5–7) and showed that 
life-threatening COVID-19 pneumonia can be caused by rare in-
born errors of autosomal genes controlling Toll-like receptor 3 
(TLR3)– and interferon (IFN) regulatory factor 7 (IRF7)–dependent 
type I IFN immunity (8). These disorders were found in 23 men 
and women aged 17 to 77 years (mean, 48 years). Four unrelated 
patients aged 25 to 50 years had autosomal recessive IFNAR1 
(n = 2) or IRF7 (n = 2) deficiency. These patients had no previous 
history of severe viral illness, including influenza pneumonia, implying 
that these genetic disorders unexpectedly show incomplete pene-
trance for critical influenza. These findings revealed that TLR3- and 
IRF7-dependent type I IFN immunity is essential for host defense 
against SARS-CoV-2 infection in the respiratory tract.
We also found preexisting neutralizing auto-antibodies (auto-Abs) 
against type I IFN in at least 10% of the patients from this cohort 
(9). These auto-Abs were found in 101 patients, mostly men (95%), 
and older members of the cohort, which included patients with in-
born errors, as they were aged 25 to 87 years (mean, 65 years). These 
findings have been replicated in five other cohorts (10–15). These 
auto-Abs predated SARS-CoV-2 infection and were highly likely to 
be causal for critical COVID-19 pneumonia, because (i) they were 
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found in samples drawn before infection in some patients (9), (ii) 
they were found in about 0.3% of the general population before the 
age of 65 years (9), (iii) they were absent from patients with asymp-
tomatic or paucisymptomatic (mild) SARS-CoV-2 infection (9), (iv) 
they were of childhood onset in patients with various disorders—
including autoimmune polyendocrinopathy type I—known to be at 
very high risk of life-threatening COVID-19 (16), and (v) they have 
been shown to underlie a third of adverse reactions to the live atten-
uated viral vaccine for yellow fever (17). Collectively, these studies 
showed that type I IFNs are essential for protective immunity to 
SARS-CoV-2 in the respiratory tract but are otherwise unexpected-
ly redundant. Auto-Abs against type I IFNs also provide a first ex-
planation for both the biased sex ratio and the higher risk of critical 
COVID-19 in patients over the age of 65 years. Here, we tested the 
hypothesis that critical and unexplained COVID-19 pneumonia in 
men may be due to rare variants on the X chromosome.
RESULTS
Enrichment for very rare TLR7 nonsynonymous variants 
in male patients
We tested the hypothesis of genetic homogeneity for X-linked re-
cessive (XR) disorders in male individuals with critical COVID-19 
pneumonia (hereafter referred to as “patients”; see Materials and 
Methods). We analyzed an international cohort of 1202 unrelated 
male patients aged 6 months to 99 years (mean, 52.9 years) that had 
no known inborn errors of TLR3- and IRF7-dependent type I IFN 
immunity (8) and without neutralizing auto-Abs against type I 
IFNs (9) [reported in an accompanying paper (18)] (table S1). We 
also analyzed 331 asymptomatic or paucisymptomatic infected 
male participants aged 1.3 to 102 years (mean, 38.7 years), with pos-
itive results for polymerase chain reaction (PCR) and/or serological 
screening for SARS-CoV-2 infection (hereafter referred to as “con-
trols”) (table S1). We sequenced the exomes (n = 1035) or genomes 
(n = 498) of these patients and controls. We selected in-frame and 
out-of-frame nonsynonymous variants of protein-coding exons 
that are very rare, that is, with a minor allele frequency (MAF) be-
low 10−4 in the full gnomAD database (v2.1.1) containing sequences 
from both male and female individuals. We compared the propor-
tions of patients and controls carrying at least one qualifying vari-
ant, by Firth bias-corrected logistic regression adjusted for age and 
ethnicity (fig. S1A) (19). We found nonsynonymous variants in at 
least five patients for 226 of 731 genes on the X chromosome, result-
ing in a Bonferroni-corrected significance threshold of 2.2 × 10−4 
(data file S1). TLR7 was the highest ranked of these genes (uncor-
rected P = 3.5 × 10−5) and the only gene that remained significant 
after correction for multiple testing (corrected P = 7.8 × 10−3), with 
21 unrelated patients carrying one very rare (n = 4 patients), two 
very rare (n = 1 patient), or one private (n = 16 patients) nonsynon-
ymous variant (Fig. 1A and table S2). One variant (L988S) was re-
current, found in three patients, including a patient carrying two 
very rare variants (M854I and L988S). No such variants were found in 
the controls. The same analysis performed on very rare (MAF < 10−4) 
synonymous TLR7 variants showed no enrichment in patients (one 
carrier) relative to controls (three carriers).
Human TLR7 is an endosomal receptor of ribonucleic acids ex-
pressed by B cells and myeloid subsets (20–24), the stimulation of 
which in plasmacytoid dendritic cells (pDCs) results in the produc-
tion of large amounts of type I IFN (25–27). We observed no 
significant enrichment for coding nonsynonymous variants of the 
X-linked gene TLR8 (P = 0.68; table S2), the product of which, TLR8, 
is endosomal and can be stimulated by some synthetic TLR7 agonists, 
with an expression pattern and signaling pathway overlapping those 
of TLR7 (28, 29). Unlike TLR7, TLR8 is expressed on granulocytes 
but not on pDCs, possibly accounting for its gain-of-function mu-
tations underlying a phenotype different from type I interferonopathies 
(30–32). Overall, we found an enrichment in very rare or private non-
synonymous TLR7 variants among the male patients with critical 
COVID-19 pneumonia (n = 21, 1.7%) of our cohort (n = 1202), includ-
ing one man over the age of 60 years.
The TLR7 mutant alleles of 16 of the 21 unrelated  
patients with critical COVID-19 pneumonia  
are biochemically deleterious
The 21 unrelated patients carried 20 different TLR7 alleles. We ex-
pressed the 20 TLR7 mutant proteins in human embryonic kidney 
(HEK) 293T cells, which have no endogenous TLR7 and TLR8 ex-
pression (33), by transient transfection with the corresponding com-
plementary DNAs (cDNAs). Immunoblotting of protein extracts 
with a TLR7-specific monoclonal Ab (mAb) showed an absence of 
TLR7 protein for p.N158Tfs*11 and p.L227fs* and the presence of 
truncated proteins for K684* and F670Lfs*8 (Fig.  1B). The other 
mutant TLR7 proteins were produced in normal amounts (Fig. 1B). 
We tested their function by cotransfection with a nuclear factor B 
(NF-B)–specific luciferase reporter. We measured luciferase activ-
ity upon stimulation with R848, an agonist of both TLR7 and TLR8 
(Fig. 1C). Twelve of the 20 alleles were loss of function (LOF) (in-
cluding L988S in two patients and M854I;L988S in another), three 
(p.L372M, p.I657T, and p.P715S) were hypomorphic (<25% activity), 
and the remaining five were neutral (Fig. 1C and data file S2). Sim-
ilar results were obtained with imiquimod and CL264, two TLR7- 
specific agonists (fig. S1, B and C). We also tested eight other private 
(p.S301P, p.Q710Rfs*18, and p.V795F), very rare (MAF < 10−4; p.A288V), 
or rare (MAF between 10−4 and 10−2; p.V219I, p.A448V, p.R920K, 
and p.A1032T) TLR7 variants previously reported in patients with 
critical COVID-19 (34, 35). These variants were expressed as trun-
cated or full-length proteins (fig. S1D). The proteins encoded by the 
three private variants were found to be LOF, that encoded by the 
very rare variant (p.A288V) was hypomorphic, and those encoded 
by the four rare variants were neutral (Fig. 1C and fig. S1B). Collec-
tively, these findings suggest that 16 of the 21 patients in our cohort 
(Table  1) and only 6 of the previously reported 12 patients carry 
deleterious TLR7 variants.
The cumulative MAF of deleterious TLR7 alleles  
is <6.5 × 10−4
We also investigated the production and function of all 100 remain-
ing nonsynonymous TLR7 variants identified in the general popu-
lation (141,456 individuals in gnomAD v2.1) that had been reported 
in men or had a general MAF of >10−5 (Fig. 1D, fig. S1E, and data 
file S2). In total, 96 of these variants were missense, and three were 
in-frame small deletions; 10 were weakly expressed, whereas the 
others had normal levels of expression (fig. S1F and data file S2). 
One variant was a small deletion creating a frameshift found in one 
man and resulting in an absence of protein production (fig. S1F and 
data file S2). Seven of the 100 variants were LOF, and 15 were hypo-
morphic (<25% activity) (data file S2). There were, thus, 24 delete-
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in four patients with critical COVID-19 pneumonia. Each of these 
24 deleterious variants had an individual MAF of <1.3 × 10−4 in men, 
and their cumulative MAF in men was 6.5 × 10−4 (data file S2 and 
table S3). The cumulative MAF of strictly LOF TLR7 alleles (excluding 
hypomorphic alleles) in men is about 2.2 × 10−4 (data file S2). Over-
all, we found 12 LOF and 3 hypomorphic TLR7 alleles in 16 unrelated 
men with critical COVID-19 pneumonia, whereas deleterious al-



























































































































































































































































































































































































































































































































































































































































Fig. 1. Enrichment in rare TLR7 deleterious alleles among men with critical COVID-19 pneumonia. (A) Manhattan plot showing the results of the variant enrichment test 
for the 190 genes of the X chromosome with at least five patients carrying nonsynonymous variants. The gray line indicates the corresponding Bonferroni-corrected significance 
threshold. (B) Western blot of extracts from nontransfected HEK293T cells (mock), HEK293T cells transfected with pCMV6 empty vector (EV), the WT TLR7 allele, or one of the TLR7 
variant alleles of interest. All extracts were probed with mAbs specific for the leucine-rich repeats to the N terminus (N-ter) or amino acid 1000 to the C terminus (C-ter) within 
the human TLR7 protein. GAPDH, glyceraldehyde-3-phosphate dehydrogenase; MW, molecular weight. (C and D) Luciferase assay on HEK293T cells transfected with the 
pGL4.32 luciferase reporter construct and an expression vector for Renilla luciferase together with no vector (mock), EV, WT, or TLR7 variants: (C) 21 variants found in our cohort 
and eight previously reported variants and (D) 109 variants found in male individuals from the gnomAD database. After 24 hours, transfected cells were left untreated or were 
treated by incubation with R848 (1 g/ml) for 24 hours. These data were established from two independent experiments. The y axis represents NF-B transcriptional activity as 
a percentage of the WT. The x axis indicates the alleles used for transfection. (E) Diagram showing the correlation between allele frequency and NF-B activity (percentage of 
WT). The 20 variants from 21 patients with critical SARS-CoV-2 from our cohort are shown in red, one variant from two patients with severe SARS-CoV-2 from our cohort are 
shown in green, the eight previously reported variants are shown in blue and the 109 variants found in the general population (allele frequency above 10−5 in men) are shown 
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infection. Moreover, deleterious TLR7 alleles in the general popula-
tion had individual and cumulative MAF values in men of <1.3 × 
10−4 and <6.5 × 10−4, respectively (Fig. 1E and data file S2). The rar-
ity of TLR7 deficiency in the general population is consistent with 
TLR7 deficiency underlying critical COVID-19. Collectively, these 
findings suggest that XR TLR7 deficiency is a genetic etiology of life- 
threatening COVID-19 pneumonia in men.
High clinical penetrance of inherited TLR7 deficiency 
in the patients’ families
The 16 patients were of three major ethnic origins, as confirmed by 
principal components analysis (PCA) of their exomes or genomes 
(36), and they were resident in seven countries (France, n = 2; Spain, 
n = 3; Italy, n = 3; Turkey, n = 2; Sweden, n = 1; Iran, n = 4; Colombia, 
n = 1) (Fig. 2, A and C; Table 1; fig. S1; and data file S3). The patients 
were hospitalized for critical COVID-19 between March 2020 and 
June 2021. Blood samples (diluted 1:10) from these 16 patients con-
tained no auto-Abs neutralizing IFN-2 and/or IFN- (10 ng/ml) 
(9, 18). The patients were aged 7 to 71 years, and their mean age was 
lower than that of the total cohort (mean age of 34.4 years versus 
52.9 years for the total cohort, in which age ranged from 0.5 to 99 years). 
TLR7-deficient patients accounted for about 1.8% of the patients 
below the age of 60 years (15 patients) and 1.3% of the entire cohort 
(16 patients). Two patients died and 14 survived (Fig. 2A and Table 1). 
Sanger sequencing of the TLR7 locus in the relatives of these pa-
tients identified the deleterious alleles in 16 heterozygous women 
from 11 families and 7 hemizygous men from seven families (Fig. 2A). 
On the basis of the 10 DNA samples available from the patients’ mothers, 
only one of the TLR7 variants (L372M) was de novo in the index case. 
Five of the seven hemizygous relatives of the index cases had Abs 
against SARS-CoV-2 (Fig.  2A and data file S3). One 29-year-old 
adult (kindred J, P11) was hospitalized for critical pneumonia, and 
another 27-year-old adult (L.II.3) was hospitalized for severe pneu-
monia [with low-flow oxygen (<6 liter/min)]. The remaining three 
were two 5-year-old boys, one of whom had been hospitalized for 
moderate COVID-19 pneumonia (without oxygen therapy) (D.II.2) 
and the other having no relevant clinical history (M.II.2), and one 
38-year-old adult with no relevant clinical history (E.II.4) (data file 
S3). The other two male carriers did not report SARS-CoV-2 infec-
tion and had negative serological results for Abs against the SARS-
CoV-2 S and N proteins.
Inherited TLR7 deficiency in patients with severe 
COVID-19 pneumonia
Given these results, we also analyzed 262 other, unrelated male pa-
tients with severe (but not critical) COVID-19 pneumonia (mean 
age, 51.0 years). We identified a new private LOF variant (p.N75H) 
in two male patients from two Turkish families (P18 and P19), aged 
12 and 7 years, respectively, who were subsequently found to be fourth- 
degree relatives (Figs. 1, B to D, and 2B; fig. S1B; and data files S2 
and S3). Their mothers are heterozygous for this variant. The clini-
cal penetrance of critical COVID-19 in men is therefore high, but 
not complete, and TLR7 deficiency can also underlie severe COVID-19. 
The absence of biochemically deleterious TLR8 variants in our cohort 
of patients with critical COVID-19 (fig. S2) and its lack of expression 
on pDCs suggest that TLR8 is not a modifier of the SARS-CoV-2–
related clinical phenotype of TLR7 deficiency, although it is adjacent 
to TLR7 on the X chromosome and can be stimulated by overlap-
ping molecules. Perhaps more relevant to the understanding of the 
incomplete penetrance is the age of the patients. Of the 23 male 
Table 1. X-linked TLR7 deleterious variants in 16 unrelated male patients with life-threatening COVID-19 pneumonia. GME Variome, Greater Middle 
Eastern Variome Project. 
Patient Genotype Age (years) Ethnicity Ancestry/residence Outcome
P1 L134P/Y 45 Admixed American Paraguay/Spain Survived
P2 N158Tfs11*/Y 60 European France Deceased
P3 L227fs*/Y 34 Middle East Iran Survived
P4 D244Y/Y 13 Middle East Turkey Survived
P5 F310L/Y 39 Middle East Iran Survived
P6 L372M 7 Caucasian (Central Asia based on GME Variome) Iran Survived
P7 I505T/Y 55 European Italy Survived
P8 H630Y/Y 50 European Spain Survived
P9 I657T/Y 18 European Italy Survived
P10 F670Lfs*8 31 European Sweden Survived
P11* F670Lfs*8 29 European Sweden Survived
P12 K684*/Y 30 European Spain Survived
P13 P715S/Y 40 Latino Colombia Survived
P14 H781L/Y 13 Middle East Russia/France Survived
P15 L988S/Y 26 Middle East Iran Deceased
P16 L988S/Y 20 Middle East Turkey Survived
P17 M854I;L988S/Y 71 European Italy Survived
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Fig. 2. XR TLR7 deficiency in 16 kindreds. (A) Pedigrees of the 16 kindreds containing 17 patients with life-threatening COVID-19 pneumonia (P1 to P17) bearing deleterious TLR7 
alleles. The mutations are indicated above each pedigree. Solid black symbols indicate patients with critical COVID-19, solid dark gray symbols indicate severe cases, and solid light 
gray symbols indicate mild/moderate cases. The genotype is indicated under each symbol, with M corresponding to the mutation found in each kindred. “+” and “−” indicate the 
presence and absence, respectively, of Abs against SARS-CoV-2 in the serum of the individual. Asymptomatic or paucisymptomatic family members hemizygous for the mutation 
are indicated by bold vertical lines. (B) Pedigree of one kindred containing two patients with severe COVID-19. (C) Schematic representation of TLR7. The upper part represents the 
genomic organization of the TLR7 locus, with rectangles for the various exons of the gene, and exon numbers indicated within the rectangle. The bottom part shows the primary 
structure of TLR7. The N-terminal portion and the leucine-rich repeat containing 26 leucine residues are located in the lumen of the endosome, and TM indicates the transmembrane 
domain. The Toll/IL-1 receptor (TIR) domain is cytoplasmic. The deleterious mutations reported in this study are indicated. (D) TLR7 expression in unstimulated EBV-B cells from two 
patients with XR TLR7 deficiency (P12 and P14), the fathers of P12 and P14, and the mother of P12, and three healthy donors (controls 1 to 3), determined by Western blotting with 
detection with a specific TLR7 Ab. (E) TNF production by XR TLR7-deficient EBV-B cells from two independent experiments. Cells were either left untreated or were stimulated with 
imiquimod (5 g/ml; gray) or PMA (25 ng/ml) and 0.25 M ionomycin (black) for 24 hours, and TNF production were measured by ELISA. (F) TNF production in XR TLR7-deficient 
EBV-B cells reexpressing WT TLR7 from three independent experiments. EBV-B cells from a control, P12, P14, or an UNC-93B–deficient patient, cultured in the presence of IRAK4 in-
hibitor (PF06650833; 5 M) were transduced with lentiviral particles that were empty or contained the WT TLR7 or mutant TLR7 cDNA. The cells were incubated for 24 hours without 
IRAK4 inhibitor and were then left untreated or were stimulated with imiquimod (5 g/ml; light gray), R848 (1 g/ml; dark gray), or PMA (25 ng/ml) and 0.25 M ionomycin (black) 
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patients carrying deleterious alleles of TLR7 infected with SARS-
CoV-2, the 20 patients who developed severe (n = 3) or critical (n = 17) 
COVID-19 were aged 7 to 71 years (mean, 32.4 years), whereas the 
three patients who developed asymptomatic, mild, or moderate in-
fection were younger: 5, 5, and 38 years (mean, 16 years). Blood 
pDC counts decrease with age (37–39), and this may contribute to 
the apparent increase in penetrance with age. In addition, a VirScan 
study of the serum samples of five index cases and three TLR7 hem-
izygous relatives revealed prior infection with diverse viruses (fig. 
S3). None had previously been hospitalized for a severe viral illness, 
including influenza pneumonia. This cohort of patients thus sug-
gests that TLR7 deficiency does not underlie severe disease caused 
by common viral infections other than SARS-CoV-2, or if so, with 
lower penetrance.
Deleterious TLR7 alleles abolish B cell responses 
to TLR7 agonists
As a first approach to testing the impact of deleterious TLR7 alleles 
in the patients’ cells, we tested Epstein-Barr virus–transformed 
B cell lines (EBV-B cells) from healthy controls and patients carrying 
the hemizygous p.K684* (P12) or p.H781L (P14) variants. The en-
dogenous expression of the p.H781L TLR7 protein was normal, 
whereas p.K684* generated a truncated protein (Fig.  2D). In re-
sponse to agonists of TLR7 (imiquimod) or TLR7 and TLR8 (R848), 
the EBV-B cell lines carrying these two mutations failed to produce 
tumor necrosis factor (TNF; Fig. 2E and fig. S4, A and B). The len-
tiviral transduction of these TLR7-deficient EBV-B cells (from P12 
and P14) with a wild-type (WT) TLR7 cDNA was unsuccessful, de-
spite numerous attempts, and this was also the case for control 
EBV-B cells, perhaps because the overproduction of TLR7 is toxic 
in B cells (40). Consistent with this view, we were able to express this 
cDNA in interleukin-1 (IL-1) receptor–associated kinase 4 (IRAK4)– 
or myeloid differentiation factor 88 (MyD88)–deficient EBV-B cells. 
We therefore investigated whether the addition of an IRAK4 inhibitor 
(PF06650833) would permit the expression of WT TLR7 in control 
and TLR7-mutated EBV-B cells. This approach was successful, and 
WT TLR7 expression restored responses to TLR7 agonists (after re-
moval of the inhibitor) (Fig. 2F and fig. S4C). Hemizygosity for LOF 
TLR7 alleles thus abolished responses to TLR7 stimulation in EBV-B 
cells, a phenotype that was rescued by WT TLR7 expression. Collec-
tively, these findings further suggest that XR TLR7 deficiency is a 
genetic etiology of severe/critical COVID-19 pneumonia.
The TLR7-mutated patients’ myeloid cells, including pDCs, 
do not respond to TLR7 agonists
Human TLR7 is known to be expressed and functional only in leuko-
cyte subsets: plasmacytoid and myeloid DCs [pDCs and myeloid 
(mDCs)], monocytes (classical, intermediate, and nonclassical), and 
B cells (28, 33, 41). TLR8 is expressed in mDCs but not pDCs, mono-
cytes but not B cells, and neutrophils (unlike TLR7) (28, 33, 41). Neither 
TLR7 nor TLR8 mRNAs have been detected in the lung or pulmo-
nary epithelial cells (42). Deep immunophenotyping by cytometry 
by time-of-flight in seven patients with TLR7 deficiency revealed no 
major abnormalities in 18 peripheral blood leukocyte subsets, includ-
ing pDCs, mDCs, monocytes, and B cells (Fig. 3A and fig. S5A). We 
previously reported inherited IRF7 deficiency in a child with critical 
influenza pneumonia (5) and two unrelated adults with critical 
COVID-19 pneumonia (8). This defect disrupts the amplification of 
type I IFNs in all cell types, including pDCs, which are normally the main 
producers of type I IFN upon blood cell stimulation with TLR7 ago-
nists or viruses, due to their constitutive expression of IRF7 (28, 43–45). 
We hypothesized that TLR7 deficiency in pDCs impairs the produc-
tion of type I IFN by these cells in response to single-stranded RNA. 
We confirmed that TLR7 was expressed on pDCs and that TLR8 was 
not (Fig. 3B and fig. S5, B and C). We measured the production of 
type I IFNs by purified leukocyte subsets (pDCs, mDCs, monocytes, 
B cells, and T cells), in response to TLR7, TLR8, and TLR9 agonists 
(Fig. 3C and fig. S5D). We confirmed that pDCs produced 100 to 
1000 times more type I IFN per cell than other leukocyte subsets 
upon TLR7 stimulation (Fig. 3C and fig. S5D). We purified pDCs 
from P8 and P14 and analyzed their production of type I IFNs in 
response to CL264 and class C CpG oligonucleotide (CpG-c), rela-
tive to that of pDCs from healthy relatives, using a cytometric bead 
array (CBA) (Fig. 3D). pDCs from P8 and P14 did not produce type I 
IFNs (or IL-6) upon stimulation with a TLR7 agonist, whereas they 
responded to a TLR9 agonist (Fig. 3D). Moreover, agonist-induced 
up-regulation of programmed death ligand 1 (PD-L1) and CD80 
defines the maturation of pDCs into the S1 (PD-L1high/CD80low), S2 
(PD-L1high/CD80high), and S3 (PD-L1low/CD80high) subsets (46). 
This maturation was not observed in the pDCs of P8 and P14 but 
was detected in the pDCs of healthy relatives and controls (Fig. 3E 
and fig. S5E). Thus, pDCs from patients with TLR7 mutations do 
not respond to TLR7 agonists in terms of maturation into special-
ized subsets and type I IFN production.
The TLR7-deficient patients’ pDCs respond poorly 
to SARS-CoV-2
A plausible mechanism accounting for the severity of COVID-19 in 
TLR7-deficient patients is the impairment of type I IFN production 
by pDCs upon stimulation with SARS-CoV-2, which can enter these 
cells but cannot replicate productively within them (46, 47). We pre-
viously showed that the activation of human pDCs by SARS-CoV-2 
depends on IRAK4 and UNC-93B but not TLR3 (46). We tested the 
hypothesis that TLR7 is an essential pDC sensor of SARS-CoV-2, 
upstream from IRAK4 and UNC-93B, by infecting pDCs and 
pDC-depleted leukocytes from healthy controls and TLR7-deficient 
patients with SARS-CoV-2 for 24 hours. Control pDC-depleted leuko-
cytes infected with SARS-CoV-2 displayed no significant up- or down- 
regulation of gene expression (fig. S6A). By contrast, transcriptomic 
analysis showed a strong up-regulation of the type I IFN transcrip-
tional module in pDCs from healthy controls, which was greatly 
reduced in pDCs from TLR7-deficient patients (Fig. 4A). Induction 
of the 17 type I IFN genes in pDCs from TLR7-deficient patients 
was 10 to 100 times weaker than that in pDCs from healthy individ-
uals (Fig. 4B and fig. S6B). We also analyzed the functional special-
ization of pDC subsets (S1, S2, and S3 pDC subsets) in response to 
SARS-CoV-2 activation (46,  48). pDCs from P14 cultured with 
SARS-CoV-2 for 24 hours displayed abnormally low levels of matu-
ration into the S1 subset, the pDC subset principally responsible for 
IFN- production upon SARS-CoV-2 infection (fig. S6C). Last, we 
evaluated the amount of type I IFNs secreted by SARS-CoV-2– 
infected pDCs. All 13 individual IFN- forms were produced in 
significantly smaller amounts by TLR7-deficient pDCs than by con-
trol pDCs (Fig. 4C and fig. S6D). However, IFN- production by 
TLR7-deficient pDCs upon SARS-CoV-2 infection was impaired 
but not entirely abolished, as in UNC-93B– or IRF7-deficient pDCs 
(8, 46), implying that there are also TLR7-independent sensors of 









Asano et al., Sci. Immunol. 6, eabl4348 (2021)     19 August 2021
S C I E N C E  I M M U N O L O G Y  |  R E S E A R C H  A R T I C L E
8 of 22
TLR7-deficient pDCs’ normal response to TLR9 agonists (Figs. 3D 
and 4, A and B, and fig. S6D) is consistent with this hypothesis, while 
also suggesting that genetic or epigenetic variations of TLR9 responses 
may contribute to the apparently age-dependent penetrance of TLR7 
deficiency. Thus, SARS-CoV-2 triggers 
type I IFN induction in pDCs in a man-
ner that is dependent on TLR7, but not 
exclusively so. Because pDCs are nor-
mally the main leukocytes producing 
type I IFN under such conditions and 
type I IFN is essential for protective im-
munity to SARS-CoV-2 (8, 9), these find-
ings suggest that XR TLR7 deficiency 
underlies critical or severe COVID-19 
pneumonia by disrupting TLR7- and 
pDC-dependent type I IFN production.
DISCUSSION
We report XR TLR7 deficiency as a ge-
netic etiology of severe/critical COVID-19 
pneumonia in 20 unrelated male patients, 
aged 7 to 71 years, from seven countries. 
Only one of these 20 patients (5%) was 
older than 60 years, consistent with our 
previous observation that only 5 of 23 pa-
tients (21.7%) with inborn errors of TLR3- 
dependent type I IFN immunity were 
older than 60 years (8). This suggests that 
these genetic defects are mostly found 
in the youngest patients. This contrasts 
with the situation for auto-Abs against 
type I IFNs, which are found mostly in pa-
tients over the age of 60 years (8, 9, 18). 
Patients with these auto-Abs do not over-
lap with those bearing inborn errors of 
TLR3- or TLR7-dependent type I IFNs. 
TLR7-deficient patients accounted for 
about 1.8% of the unrelated male pa-
tients with critical COVID-19 pneumo-
nia below the age of 60 years in our cohort 
and accounted for 1.3% of the total co-
hort. This proportion remained around 
the same when severe COVID-19 pneu-
monia was also taken into account (1.7% 
males below 60 years; 1.2% of all the 
male patients in the total cohort). We 
also found that six of the 12 previously 
reported patients with a TLR7 variant 
had TLR7 deficiency (34, 35). It would 
be interesting to test experimentally the 
undisclosed TLR7 variants reported to 
be enriched in another study (49). Our 
discovery provides an explanation for 
the higher risk of severe and critical dis-
ease in men than in women under the age 
of 60 years, complementing our previ-
ous observation of a much higher fre-
quency of neutralizing auto-Abs against 
type I IFNs in men than in women with critical COVID-19 pneu-
monia for patients over the age of 60 years (9).
Previous reports of patients with critical COVID-19 pneumonia 
due to inborn errors of TLR3-dependent type I IFN immunity (8), 
Fig. 3. Type I IFN responses to TLR7 agonist in TLR7-deficient pDCs and leukocytes. (A) Frequencies of five leuko-
cyte subsets in whole blood, determined by CyTOF. Healthy donors (black rectangles), relatives not carrying deleterious 
TLR7 alleles (blue rectangles) and hemizygous TLR7 variant carriers (red rectangles) are depicted. (B) TLR7 and TLR8 
expression in different leukocyte subsets, determined by flow cytometry for the healthy control (C1). The result for an-
other healthy control (C2) is shown in fig. S5C. Gating strategy for the classification in each cell subset is shown in data 
file S6. NK, natural killer. (C) IFN- production in purified leukocyte subsets from two healthy donors (blue or yellow dot) 
with and without stimulation with various TLR7, TLR8, or TLR9 agonists [CL264 (1 g/ml), TL8-506 (100 ng/ml), R848 
(1 g/ml), or 2 M CpG-c] for 24 hours. The y axis shows IFN- production on a logarithmic scale. The red bar corresponds 
to pDCs. (D) pDCs isolated from healthy donors and TLR7-deficient patients (P8 and P14) were either left untreated 
(medium) or were stimulated with CL264 or CpG-c, and the production of IFN-2 and IL-6 was assessed with CBAs on 
the supernatant. (E) Dot plot showing pDC diversification into subsets S1, S2, and S3 from magnetically sorted blood. 
pDCs from a TLR7-deficient patient (P14) and a healthy relative (M.I.1) were cultured for 24 hours with medium alone or 
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including autosomal recessive IRF7 or IFNAR1 deficiency (5, 6), or 
due to auto-Abs neutralizing type I IFNs (9, 11–14, 16, 17), strongly 
suggest that critical disease in TLR7-deficient patients is a conse-
quence of impaired type I IFN production upon SARS-CoV-2 in-
fection. The absence of biochemically deleterious X-linked TLR8 
variants in our cohort of patients suggests that TLR8 is not essential 
for host defense against SARS-CoV-2. This is consistent with the 
modest capacity of TLR8 to induce type I IFN and its lack of expres-
sion on pDCs (28) and with the inflammatory phenotype of TLR8 
gain-of-function mutations, which do not underlie a type I interfer-
onopathy (30–32). Patients with inherited IRAK4 or MyD88 defi-
ciency, whose cells do not respond to the stimulation of IL-1Rs and 
TLRs other than TLR3, including TLR7, have not been reported to 
display any severe viral illness over the almost 20 years since the 
discovery of IRAK-4 deficiency (50–53). Moreover, UNC-93B– 
deficient pDCs produced normal amounts of type I IFN in response 
to seasonal influenza virus (5). This was intriguing, as strong nega-
tive selection operates at the human TLR7, TLR8, and TLR9 loci 
(50, 54). Our study provides an answer to this riddle, by establishing 
that TLR7 is essential for protective immunity to SARS-CoV-2. Pa-
tients with IRAK4, MyD88, or UNC-93B deficiency are now pre-
dicted to be vulnerable to SARS-CoV-2 (55–57). Critical COVID-19 
and seasonal influenza can be caused by inborn errors of TLR3- 
dependent type I IFN immunity (5–8), but susceptibility to these 
infections is not allelic at the TLR7 locus. It is, nevertheless, tempt-
ing to speculate that TLR7 might also be essential for host defense 
against more virulent, pandemic viruses, including both corona-
viruses and influenza viruses.
Through the discovery of the essential nature of TLR7 for the 
induction of type I IFN in response to SARS-CoV-2, our study also 
reveals the essential function of human pDCs in host defense. The 
constitutively high levels of IRF7 in these cells make them the most 
potent producers of type I IFN in the blood, and perhaps in the entire 
human body, and this has long suggested a possible key role in anti-
viral immunity (26). However, the essential and redundant roles of this 
leukocyte subset have yet to be determined, in the absence of human 
pDC-specific deficiencies causally underlying a clinical phenotype. 
It has long been suspected, but never proved, that pDCs are essential 
for host defense under natural conditions (27, 58–60). Inherited IRF7 
deficiency, which underlies critical influenza or COVID-19 pneu-
monia, disrupts the production of type I IFNs not only by pDCs (5, 8) 
but also by all other cell types, including pulmonary epithelial cells (5). 
Likewise, patients with GATA2 deficiency, who are prone to critical 
influenza (61), lack pDCs, but these patients also lack many other 
blood cell subsets (62–65). Inherited IFNAR1 deficiency underlies 
critical COVID-19 probably due to its broad cellular impact (5, 6, 8). 
By contrast, inborn errors of the TLR3 pathway underlie critical in-
fluenza or COVID-19 pneumonia by impairing the production of 
type I IFNs by cells other than pDCs, such as pulmonary epithelial cells 
(5–8, 66). Our study indicates that pulmonary epithelial cells are not 
sufficient for host defense against SARS-CoV-2, as these cells do not 
express TLR7. Inborn errors of TLR7 are pathogenic by impairing 
the production of type I IFNs by blood pDCs, which are unique in 
their production of large amounts of both TLR7 and IRF7 (67, 68). 
pDCs express other viral sensors, including TLR9 (for DNA), mela-
noma differentiation-associated protein 5 (MDA5), and retinoic 
Fig. 4. Type I IFN responses to SARS-CoV-2 infection in TLR7-deficient pDCs. (A) pDCs isolated from healthy relatives and TLR7-deficient patients (P8 and P14) were 
either left untreated or were infected with SARS-CoV-2 for 24 hours. RNA profiles were then determined by RNA-seq. Genes with an expression of >2.0-fold higher or 
lower in controls after stimulation or infection are plotted as the fold change in expression. (B) Induction of the type I and III IFN genes from (A) infected with SARS-CoV-2 
for 24 hours (top) or stimulated with CpG-c (bottom). (C) pDCs isolated from healthy relatives and TLR7-deficient patients (P8 and P14) were either left untreated or were 
infected with SARS-CoV-2 for 24 hours, and the production of IFN-2, IP-10, IL-6, and IL-8 was measured with CBAs on the supernatant. Statistical tests were performed 
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acid-inducible gene I (RIG-I) (for double-stranded RNA) (69), but 
TLR7 deficiency impairs their capacity to produce large enough 
amounts of type I IFN in response to SARS-CoV-2 in the respiratory 
tract. Overall, by disrupting pDC-dependent type I IFN production, 
XR TLR7 deficiency accounts for at least 1% of cases of life-threatening 
COVID-19 pneumonia in men under 60 years.
MATERIALS AND METHODS
Study design
We searched for X-linked inborn errors of immunity in male patients 
with critical SARS-CoV-2 pneumonia. We screened our whole-exome 
sequencing (WES) database of 1202 male patients with critical 
SARS-CoV-2 pneumonia (patients) and 331 male participants with 
asymptomatic or paucisymptomatic infection (controls). We tested the 
association of X-linked genes with critical SARS-CoV-2 pneumonia 
using a Firth bias-corrected logistic regression model including the 
first five principal components of the PCA to account for the ethnic 
heterogeneity of the cohorts and age in years. We then tested the 
activity of TLR7 variants in transduced cell lines and of TLR7 geno-
types in hemizygous patients’ cell lines. Last, we tested the patients’ 
pDCs for their response to both TLR7 agonists and SARS-CoV-2.
Cohort recruitment and consent
This study included 1202 male patients with life-threatening COVID-19 
pneumonia, defined as patients with pneumonia who developed criti-
cal disease, whether pulmonary with high-flow oxygen (>6 liter/min) 
or mechanical ventilation [continuous positive airway pressure (CPAP), 
bilevel positive airway pressure (BIPAP), and intubation], septic shock, 
or any other type of organ damage requiring intensive care unit ad-
mission. This study also included patients with severe COVID-19 
pneumonia, defined as hospitalized patients with pneumonia that 
required low-flow oxygen (<6 liter/min); moderate COVID-19 pneu-
monia, defined as patients with pneumonia but did not require oxygen 
therapy; and mild COVID-19, defined as patients with mild upper 
respiratory symptoms but without pneumonia. Patients who devel-
oped Kawasaki-like syndrome were excluded. The age of the patients 
ranged from 0.5 to 99 years, with a mean age of 52.9 years (SD, 
16.4 years). Asymptomatic or paucisymptomatic individuals (n = 331) 
were recruited on the basis of positive PCR or serological tests for 
SARS-CoV-2 in the absence of symptoms. These individuals were 
close contacts of patients or were recruited after clinical screening. 
The age of the asymptomatic or paucisymptomatic individuals ranged 
from 1.3 to 102 years, with a mean age of 38.7 years (SD, 17.2 years).
All the enrolled participants provided written informed consent 
and were collected through protocols conforming to local ethics 
requirements. For patients enrolled in the French COVID cohort 
(ClinicalTrials.gov NCT04262921), ethics approval was obtained from 
the Comité de Protection des Personnes Ile De France VI (ID RCB, 
2020-A00256-33) or the Ethics Committee of Erasme Hospital 
(P2020/203). For participants enrolled in the COV-Contact study 
(ClinicalTrials.gov NCT04259892), ethics approval was obtained from 
the CPP IDF VI (ID RCB, 2020-A00280-39). For patients enrolled 
in the Italian cohort, ethics approval was obtained from the Univer-
sity of Milano-Bicocca School of Medicine, San Gerardo Hospital, 
Monza–Ethics Committee of the National Institute of Infectious 
Diseases Lazzaro Spallanzani (84/2020) (Italy), and the Comitato Etico 
Provinciale (NP 4000–Studio CORONAlab). STORM-Health care 
workers were enrolled in the STudio OsseRvazionale sullo screening 
dei lavoratori ospedalieri per COVID-19 (STORM-HCW) study, with 
approval from the local institutional review board (IRB) obtained 
on 18 June 2020. Patients and relatives from San Raffaele Hospital 
(Milan) were enrolled in protocols COVID-BioB/Gene-COVID and, 
for additional studies, TIGET-06, which were approved by local 
ethical committee. For patients enrolled in Spain, the study was 
approved by the Committee for Ethical Research of the Infanta 
Leonor University Hospital, code 008-20; Committee for Ethical 
Research of the University Hospital 12 de Octubre, code 16/368; the 
Bellvitge University Hospital, code PR127/20; the University Hospital 
of Gran Canaria Dr. Negrín, code 2020-200-1 COVID-19; and the 
Vall d’Hebron University Hospital, code PR(AMI)388/2016. 
Anonymized samples were sequenced at the National Institute of 
Allergy and Infectious Diseases (NIAID) through Uniformed 
Services University of the Health Sciences (USUHS)/the American 
Genome Center (TAGC) under nonhuman subject research condi-
tions; no additional IRB consent was required at the National Insti-
tutes of Health (NIH). For patients enrolled in the Swedish COVID 
cohort, ethics approval was obtained from the Swedish Ethical Review 
Agency (2020-01911 05).
Next-generation sequencing
Genomic DNA was extracted from whole blood. For the 1533 patients 
included, the whole exome (n = 1035) or whole genome (n = 498) 
was sequenced at several sequencing centers, including the Genomics 
Core Facility of the Imagine Institute (Paris, France), the Yale Center 
for Genome Analysis (USA), the New-York Genome Center (NY, 
USA), and TAGC (USUHS, Bethesda, USA), and the Genomics 
Division–Institute of Technology and Renewable Energies (ITER) of 
the Canarian Health System sequencing hub (Canary Islands, Spain).
For WES, libraries were generated with the Twist Bioscience kit 
(Twist Human Core Exome Kit), the xGen Exome Research Panel from 
Integrated DNA Technologies (IDT; xGen), the Agilent SureSelect 
V7 Kit or the SeqCap EZ MedExome Kit from Roche, and the Nextera 
Flex for Enrichment-Exome kit (Illumina). Massively parallel se-
quencing was performed on a HiSeq 4000 or NovaSeq 6000 system 
(Illumina). For WES analysis performed at Centro Nacional de Análisis 
Genómico (CNAG) Barcelona, Spain, capture was performed with 
the SeqCap EZ Human Exome Kit v3.0 (Roche Nimblegen, USA), 
and 100–base pair (bp) paired-end read sequences were obtained on 
a HiSeq 2000-4000 platform (Illumina Inc. USA). For the Ospedale 
San Raffaele (OSR) Italian cohort, WES was performed with the 
Agilent SureSelect V7 Kit on a NovaSeq6000 system (Illumina).
For whole-genome sequencing of patients from the Italian co-
hort (TAGC), genomic DNA samples were dispensed into the wells 
of a Covaris 96 microTUBE plate (1000 ng per well) and sheared 
with the Covaris LE220 Focused-ultrasonicator, at settings target-
ing a peak size of 410 bp [t, 78; duty, 18; Peak Incident Power (PIP), 
450; 200 cycles]. Sequencing libraries were generated from frag-
mented DNA with the Illumina TruSeq DNA PCR-Free HT Library 
Preparation Kit, with minor modifications for automation (Hamilton 
STAR Liquid Handling System), with IDT for Illumina TruSeq DNA 
UD Index (96 indices, 96 samples) adapters. Library size distribu-
tion was assessed and the absence of free adapters or adapter dimers 
was checked by automated capillary gel electrophoresis (Advanced 
Analytical Fragment Analyzer). Library concentration was deter-
mined by quantitative PCR (qPCR) with the KAPA qPCR Quantifi-
cation Kit (Roche Light Cycler 480 Instrument II). Sequencing 
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quantified as above, before dilution to 2.9 nM and sequencing on an 
Illumina NovaSeq 6000 with the S4 Reagent Kit (300 cycles) and 
151 + 8 + 8 + 151 cycle run parameters. Primary sequencing data 
were demultiplexed with the Illumina HAS2.2 pipeline, and 
sample-level quality control was performed for base quality, coverage, 
duplicates, and contamination (FREEMIX < 0.05 by VerifyBamID). 
For patients enrolled in the Swedish COVID cohort, sequencing was 
performed at the Clinical Genomics Stockholm unit of the SciLifeLab 
(Stockholm, Sweden).
We used the Genome Analysis Software Kit (GATK) (version 
3.4-46 or 4) best-practice pipeline to analyze our WES data (70). We 
aligned the reads obtained with the human reference genome (hg19), 
using the maximum exact matches algorithm in the Burrows- 
Wheeler Aligner (71). PCR duplicates were removed with Picard 
tools (picard.sourceforge.net). The GATK base quality score recali-
brator was applied to correct sequencing artifacts. Genotyping was 
performed with GATK GenotypeGVCFs in the interval intersecting 
all the capture kits of ±50 bp. Sample genotypes with a coverage of 
<8×, a genotype quality of <20, or a ratio of reads for the less cov-
ered allele (reference or variant allele) over the total number of reads 
covering the position (minor read ratio) of <20% were filtered out. 
We filtered out variant sites (i) with a call rate of <50% in gnomAD 
genomes and exomes, (ii) with a non-PASS filter in the gnomAD 
database, (iii) falling in low-complexity or decoy regions, (iv) that 
were multiallelic with more than four alleles, (v) with more than 
20% missing genotypes in our cohort, and (vi) spanning more than 
20 nucleotides. Variant effects were predicted with the Ensembl Vari-
ant Effect Predictor (72) and the Ensembl GRCh37.75 reference 
database, retaining the most deleterious annotation obtained from 
Ensembl canonical transcripts overlapping with RefSeq transcripts.
Statistical analysis
We performed an enrichment analysis focusing on X chromosome 
genes on our cohort of 1202 male patients with life-threatening 
COVID-19 pneumonia without known inborn errors of TLR3- and 
IRF7-dependent type I IFN immunity (8) and without neutralizing 
auto-Abs against type I IFNs (9) and 331 male individuals with 
asymptomatic or paucisymptomatic infection (table S1). We con-
sidered variants that were predicted to be LOF or missense, with a 
MAF below 0.0001 (gnomAD v2.1.1). We compared the proportion 
of patients and controls carrying at least one nonsynonymous using 
the Firth bias-corrected logistic likelihood ratio test implemented 
in EPACTS (Efficient and Parallelizable Association Container 
Toolbox) (http://genome.sph.umich.edu/wiki/EPACTS) extended to 
gene-based enrichment analysis. In Firth’s regression, a penalty term 
is placed on the standard maximum likelihood function used to 
estimate parameters of a logistic regression model (19). Firth’s can 
handle genes with no carriers among cases or controls. With no co-
variates, this corresponds to adding 0.5 in every cell of a 2 by 2 table 
of allele counts versus case-control status. We accounted for the 
ethnic heterogeneity of the cohorts by including the first five prin-
cipal components of the PCA in the Firth’s logistic regression model. 
Analyses were also adjusted for age in years. We checked that our 
adjusted burden test was well calibrated by also performing an anal-
ysis of enrichment in rare (MAF < 0.0001) synonymous variants. 
PCA was performed with Plink v1.9 software on whole-exome and 
whole-genome sequencing data, with the 1000 Genomes Project 
phase 3 public database as a reference, using 18,917 exonic variants 
with an MAF of >0.01 and a call rate of >0.99.
Cell culture
EBV-B cell lines derived from the patients were grown in complete RPMI 
1640 (Life Technologies) supplemented with 10% heat-inactivated fetal 
bovine serum (FBS). HEK293T cells, derived from the HEK293 cell 
line, which expresses a mutant version of the SV40 large T antigen, 
were grown in complete Dulbecco’s modified Eagle’s medium (Life 
Technologies) supplemented with 10% FBS. Cells were incubated at 
37°C in the presence of 5% CO2.
Expression vectors and transfection experiments
All the TLR7 variants in our analysis were generated by site-directed 
mutagenesis (data file S4). The WT or variant alleles were reintro-
duced into a Myc-DDK-pCMV6 vector (OriGene). HEK293T cells, which 
have no endogenous TLR7 or TLR8 expression, were transfected with 
the Myc-DDK-pCMV6 vector, empty or containing the WT, or a vari-
ant allele, in the presence of the X-tremeGENE 9 DNA Transfection 
Reagent (Sigma-Aldrich), according to the manufacturer’s instructions.
Western blotting
For whole-cell extracts, the cells were lysed by incubation in the fol-
lowing buffer [50 mM tris-HCl (pH 8.0), 150 mM NaCl, and 1% 
NP-40), supplemented with a mixture of protease inhibitors (Sigma- 
Aldrich), for 30  min at 4°C. The lysates were then centrifuged at 
21,000g for 20 min at 4°C. The supernatants were processed directly 
for Western blotting. Western blotting was performed on 10 g of 
total extract from transfected HEK293T cells, with mAbs specific 
for the leucine-rich repeats to the N terminus within the human 
TLR7 protein (Cell Signaling Technology, clone, D7) or for amino 
acid 1000 to the C terminus with the human TLR7 protein [Abcam, 
clone, EPR2088(2)].
Luciferase reporter assay
HEK293T cells, which have no endogenous TLR7 expression, were 
transfected with the pCMV6 vector bearing WT or variant TLR7 (50 ng), 
the reporter construct pGL4.32 (100 ng), and an expression vector 
for Renilla luciferase (10 ng), with the X-tremeGENE 9 DNA Trans-
fection Reagent kit (Sigma-Aldrich). The pGL4.32 (luc2P/NF-B–
RE/Hygo) (Promega) reporter vector contains five copies of the 
NF-B–responsive element (NF-B–RE) linked to the luciferase re-
porter gene luc2P. After 24 hours, the transfected cells were left un-
stimulated or were stimulated with R848 (1 g/ml; resquimod), for 
activation via TLR7/8 (Invivogen), or R837 (5 g/ml; imiquimod) 
(Invivogen), or CL264 (5 g/ml; Invivogen), human TLR7-specific ag-
onists, for 24 hours. Relative luciferase activity was then determined by 
normalizing the values against the firefly:Renilla luciferase signal ratio.
RNA extraction and reverse transcription qPCR
Total RNA was extracted with the RNeasy Mini Kit (QIAGEN), ac-
cording to the manufacturer’s instructions. Reverse transcription 
was performed on 1 g of RNA with random primers and the 
SuperScript III reverse transcriptase (Invitrogen), according to the 
manufacturer’s protocol. qPCR was then performed with the TaqMan 
Fast Universal PCR Master Mix (2X) and the FAM-MGB TaqMan 
TNF exons 1 and 2 (Hs99999-43_m1) probes. The VIC-TAMRA 
probe for GUSB (Applied Biosystems, catalog no. 4310888E) was 
used as an endogenous control. Real-time PCR amplification was 
monitored with the 7500 Fast Real-Time PCR System (Applied 
Biosystems). Relative expression levels were determined according 









Asano et al., Sci. Immunol. 6, eabl4348 (2021)     19 August 2021
S C I E N C E  I M M U N O L O G Y  |  R E S E A R C H  A R T I C L E
12 of 22
Enzyme-linked immunosorbent assay analysis of TNF 
production in EBV-B cells
Enzyme-linked immunosorbent assay (ELISA) was performed as 
previously described (51). We suspended 1 × 106 EBV-B cells per 
well in RPMI 1640 supplemented with 10% FBS. The cells were ac-
tivated by incubation with R848 (1 g/ml) and imiquimod (5 g/
ml) for 24 hours. The supernatants were harvested after 24 hours of 
activation. ELISA determinations of TNF in cell culture superna-
tants were performed with a kit (Thermo Fisher Scientific), accord-
ing to the manufacturer’s instructions.
Stable transduction
The WT coding sequence of TLR7 was inserted into pTRIP-CMV-
puro-2A. For lentivirus production, HEK293T cells were transfect-
ed with 1.6 g of pTRIP-CMV-puro-2A-TLR7-WT (or mutant, 
K684*), 0.2 g of pCMV-VSV-G (Addgene), 0.2 g of pHXB2 
(NIH-AIDS Reagent 22 Program), and 1 g of psPAX2 (Addgene), 
with X-treme gene 9 (Roche), according to the manufacturer’s 
instructions. Supernatants were harvested after 24 hours, and 
protamine sulfate (8 g/ml) was added. The lentiviral suspension 
obtained was used to transduce 2 × 105 EBV-B cells by spinocu-
lation at 1200g for 2 hours. The transduced cells were selected by 
incubation on medium containing puromycin (1 g/ml) for 
2 days. The cells were then selected by incubation for a further 
2 days on medium containing puromycin (2 g/ml). During viral 
transduction, the cells were cultured with 5 M IRAK4 inhibitor 
(PF06650833) (Bio-Techne) to prevent cell death due to the over-
production of TLR7. Selected transduced cells were then stimulated 
with R848 (1 g/ml) or imiquimod (5 g/ml) for 24 hours without 
IRAK4 inhibitor. The supernatants were harvested after 24 hours of 
activation. ELISA determinations of TNF in cell culture superna-
tants were performed with a kit (Thermo Fisher Scientific), accord-
ing to the manufacturer’s instructions.
VirScan analysis
Patient serum was analyzed by VirScan in two independent experi-
ments as previously described (73). Briefly, an oligonucleotide li-
brary encoding 56–amino acid peptides tiling across the genomes of 
206 viral species was synthesized on a releasable DNA microarray 
and cloned into T7 phage. Patient serum containing 2 g of immu-
noglobulin G was added to the phage library, and immunoprecipi-
tation was performed with Protein A and G beads. Enriched 
peptides were identified by PCR and Illumina sequencing of the 
peptide cassette from the immunoprecipitated phage.
Deep immunophenotyping by mass cytometry (CyTOF)
CyTOF was performed on whole blood with the Maxpar Direct Im-
mune Profiling Assay (Fluidigm), according to the manufacturer’s 
instructions. Cells were frozen at −80°C after overnight staining to 
eliminate dead cells, and acquisition was performed on a Helios ma-
chine (Fluidigm). All the samples were processed within 24 hours of 
sampling. Data analysis was performed with OMIQ software. Ab in-
formation is listed in the Supplementary Materials (data file S5).
Peripheral blood mononuclear cells enrichment using 
magnetic-activated cell sorting (MACS) system
Blood were collected from two healthy individuals and separated by 
the concentration gradient method with Ficoll Paque Plus (Cytiva). 
After isolations of peripheral blood mononuclear cells (PBMCs), 
leucocyte subset (T cell, B cell, monocyte, pDC, and mDC) was pu-
rified by negative selection using MACS beads system (Miltenyi 
Biotec). Cells were plated into a U-bottomed 96-well plate at a den-
sity of 2 × 104 cells per well for T cells, B cells, monocytes, pDCs, or 
mDCs in RPMI 1640 (200 l per well) with GlutaMAX supplement-
ed with 10% FBS or 10 × 104 cells per well for whole blood and 
PBMCs. Cells were left unstimulated or stimulated with CL264 
(1 g/ml), TL8-506 (100 ng/ml; Invivogen), R848 (1 g/ml), 2 M CpG-c 
(Invivogen), or phorbol 12-myristate 13-acetate (PMA; 12.5 ng/ml) 
and 0.125 M ionomycin for 24 hours. The supernatants were har-
vested after 24 hours of activation. Cytokines production were de-
termined by ELISA [IFN-, PBL Assay Science; IFN-, PBL Assay 
Science; IFN-1 (IL-29), Invivogen; IFN-, Invitrogen; or IL-8, R&D 
Systems], according to the manufacturer’s instructions.
Analysis for TLR7 and TLR8 expression pattern in PBMCs  
by flow cytometry
Freshly thawed PBMCs from healthy donors were dispensed into a 
V-bottomed 96-well plate at a density of 1 × 106 cells per well, in 200 l 
of phosphate-buffered saline (PBS) per well. Briefly, cells were stained 
by incubation with the LIVE/DEAD fixable blue dead-cell staining 
kit (Thermo Fisher Scientific; 1:800) and Fc receptor blocking re-
agent (Miltenyi Biotec; 1:25) on ice for 15 min. For surface staining, 
cells were incubated with anti-TCR-BUV611 (BD Biosciences; 
1:50), anti–CD183-BV750 (BD Biosciences; 1:20), and anti–CD194-
BUV615 (BD Biosciences; 1:20) Abs on ice for 30 min in 0.1% bo-
vine serum albumin and 0.01% sodium azide in PBS. They were then 
incubated with anti–CD141-BB515 (BD Biosciences; 1:40), anti–
CD57-FITC (BioLegend; 1:83), anti-TCR V2-PerCP (BioLegend; 
1:166), anti-TCR V7.2-PerCP/Cyanine5.5 (BioLegend; 1:40), anti- 
TCR V1-PerCP-Vio 700 (Miltenyi Biotec; 1:100), anti–CD14-Spark 
Blue 550 (BioLegend; 1:40), anti–CD1c–Alexa Fluor 647 (BioLegend; 
1:50), anti–CD38-APC/Fire 810 (BioLegend; 1:30), anti–CD27-APC-H7 
(BD Biosciences; 1:50), anti–CD127-APC-R700 (BD Biosciences; 1:50), 
anti–CD19-Spark NIR 685 (BioLegend; 1:83), anti–CD45RA-BUV395 
(BD Biosciences; 1:83), anti–CD16-BUV496 (BD Biosciences; 1:166), 
anti–CD11b-BUV563 (BD Biosciences; 1:100), anti–CD56-BUV737 
(BD Biosciences; 1:83), anti–CD8-BUV805 (BD Biosciences; 1:83), 
anti–hMR1-BV421 (NIH Tetramer Facility; 1:100), anti–CD11c-BV480 
(BD Biosciences; 1:40), anti–CD45-BV510 (BioLegend; 1:83), anti–
CD33-BV570 (BioLegend; 1:83), anti–iNKT-BV605 (BioLegend; 
1:25), anti–CD161-BV650 (BD Biosciences; 1:25), anti–CCR6-BV711 
(BioLegend; 1:83), anti–CCR7-BV785 (BioLegend; 1:40), anti–CD3–
Pacific Blue (BioLegend; 1:83), anti–CD20–Pacific Orange (Life Tech-
nologies; 1:50), anti–CD123–Super Bright 436 (Invitrogen; 1:40), 
anti–CD24-PE–Alexa Fluor 610 (Life Technologies; 1:25), anti–CD25-
PE–Alexa Fluor 700 (Life Technologies; 1:25), anti–CD294-biotin 
(Invitrogen; 1:50), anti–CD209-PE/Cyanine7 (BioLegend; 1:25), anti–
CD117–PE/Dazzle 594 (BioLegend; 1:83), anti–HLA-DR–PE/Fire 
810 (BioLegend; 1:50), and anti–CD4–cFluor YG584 (Cytek; 1:83) 
Abs on ice for at least 30 min. The cells were then washed and stained 
by incubation with streptavidin-PE/Cy5 (BioLegend; 1:3000) on ice 
for 30 min. The cells were then fixed and permeabilized for intracel-
lular staining with anti–TLR7-PE (Invitrogen) and anti–TLR8-APC 
(BioLegend) Abs, with the eBioscience Foxp3/Transcription Factor 
Staining Buffer Set (Invitrogen), according to the manufacturer’s 
instructions. The cells were then washed and acquired with a 
five-laser Cytek Aurora (Cytek) flow cytometer. Ab clone information 
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pDC activation
Freshly purified pDCs were cultured in 96-well plates at a concen-
tration of 5 × 105 cells/ml in the presence of medium alone [RPMI 
1640 with GlutaMAX, 10% FBS, 1% minimum essential medium 
non-essential amino acid (NEAA), 1% sodium pyruvate, and 
1% penicillin/streptomycin], CL264 (Invivogen; 1 g/ml), or the 
SARS-CoV-2 primary strain 220_95 (46) at a multiplicity of infection 
of 1. After 24 hours of culture, the pDC supernatant was collected 
for cytokine quantification, and the pDCs were collected for diver-
sification assessment by flow cytometry. In some experiments, RNA 
was purified from the pDCs that were analyzed by RNA sequencing 
(RNA-seq; see below).
Flow cytometry analysis for human pDCs
For assessments of pDC diversification, cells were stained with a 
Zombie Violet fixable viability dye (BioLegend), BV711 anti-CD123 
(BioLegend, clone 6H6), PE anti-CD80 (BD Biosciences, clone L307.4), 
and PerCP–efluor 710 anti–PD-L1 (eBioscience, clone MIH1) Abs. 
Data were acquired with an LSRFortessa (BD Biosciences) flow cytom-
eter and analyzed with FlowJo software (Tree Star). Flow cytometry 
analyses were performed at the flow cytometry core facility of Institut 
de recherche Saint Louis (Paris, France).
RNA sequencing
We collected cells from five individuals in two families: one patient 
(P8) and two healthy controls (H.II.2 and H.II.3) from family H and 
one patient (P14) and one healthy control (M.I.1) from family M. 
These cells were stimulated with three conditions: nonstimulation, 
SARS-CoV-2, and CpG-c. Total RNA was extracted from pDC cells 
with RNeasy Micro kits (QIAGEN). RNA-seq libraries were pre-
pared with the Illumina SMART-Seq v4 PLUS Kit (TaKaRa) and 
sequenced on the Illumina NextSeq 4000 platform with single-end 
75-bp configuration. The RNA-seq fastq raw data were inspected 
with multiQC v1.10 (74) to ensure the high quality of data. The 
sequencing reads were mapped onto the human reference genome 
GRCh38 with STAR aligner v2.7 (75), and the mapped reads 
were then quantified to determine the gene-level read counts with 
featureCounts V2.0.2 (76) and GENCODE human gene annotation 
GRCh38.p13 (77). The gene-level read counts were normalized and 
log2-transformed by DESeq2 (78), to obtain the gene expression 
profile of all samples for differential expression analysis. The differ-
ential gene expression was analyzed by applying trimmed mean of 
M values (TMM) normalization and gene-wise generalized linear 
model regression with edgeR (79). The genes displaying signifi-
cant differential expression were selected on the basis of |log2- 
FoldChange| ≥ 2 and a false discovery rate of ≤0.05. The gene-level 
read counts of IFN genes were transformed to reads per kilobase of 
transcript, per Million mapped reads by our own scripts, to com-
pare the IFN gene expression of different samples under different 
stimulations.
Determination of secreted inflammatory cytokines
We measured the production, by pDCs, of IFN-2, IL-8, IL-6, and 
interferon gamma-induced protein 10 (IP-10), by determining the 
levels of these cytokines in culture supernatants with the BD CBA, 
according to the manufacturer’s protocol, with a limit of detection 
of 20 pg/ml. Acquisitions were performed on an LSRFortessa (BD 
Biosciences) flow cytometer, and cytokine concentrations were 
determined with FCAP Array software (BD Biosciences).
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X-linked COVID-19 risk factor
Age and male sex are two prominent risk factors for developing life-threatening COVID-19 after SARS-CoV-2 infection.
Asano et al. analyzed 1202 critical male COVID-19 patients to examine whether non-synonymous variants in genes
on the X chromosome are a risk factor for developing COVID-19 pneumonia. Toll-like receptor 7 (TLR7) variants
resulting in TLR7 deficiency occurred in 16 unrelated males, most of which were under age 60. Plasmacytoid dendritic
cells (pDCs), primary producers of type I interferon (IFN-I), from TLR7-deficient patients were unresponsive to TLR7
stimulation and displayed impaired production of IFN-I in response to SARS-CoV-2. These results identify X-linked
recessive TLR7 deficiency as a genetic risk factor for COVID-19 pneumonia in males and demonstrate a key role for
intact pDC IFN-I in protective immunity against SARS-CoV-2.
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